These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 6657927

  • 21. Response of mammary tumors of C3H/He mice to hyperthermia and bleomycin in vivo.
    Ma F, Hiraoka M, Jo S, Akuta K, Nishimura Y, Takahashi M, Abe M.
    Radiat Med; 1985; 3(4):230-3. PubMed ID: 2425397
    [Abstract] [Full Text] [Related]

  • 22. Comparative study of thermoradiosensitization by misonidazole and metronidazole in vivo: antitumour effect and pharmacokinetics.
    Wong KH, Maezawa H, Urano M.
    Int J Hyperthermia; 1992; 8(5):645-58. PubMed ID: 1402141
    [Abstract] [Full Text] [Related]

  • 23. Treatment of Dunning R3327-AT rat prostate tumors with photodynamic therapy in combination with misonidazole.
    Gonzalez S, Arnfield MR, Meeker BE, Tulip J, Lakey WH, Chapman JD, McPhee MS.
    Cancer Res; 1986 Jun; 46(6):2858-62. PubMed ID: 3698010
    [Abstract] [Full Text] [Related]

  • 24. Biodistribution of misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in rats bearing unclamped and clamped 9L subcutaneous tumors.
    Wong KH, Wallen CA, Wheeler KT.
    Int J Radiat Oncol Biol Phys; 1989 Jul; 17(1):135-43. PubMed ID: 2745188
    [Abstract] [Full Text] [Related]

  • 25. Effect of administration schedules on the potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) by misonidazole in subcutaneous 9L tumors.
    Wong KH, Zhang H, Wallen CA, Wheeler KT.
    Int J Radiat Oncol Biol Phys; 1992 Jul; 23(4):831-9. PubMed ID: 1618675
    [Abstract] [Full Text] [Related]

  • 26. Combined adriamycin and hyperthermia treatment of a murine mammary carcinoma in vivo.
    Overgaard J.
    Cancer Res; 1976 Sep; 36(9 pt.1):3077-81. PubMed ID: 975075
    [Abstract] [Full Text] [Related]

  • 27. The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay.
    Horsman MR, Overgaard J, Chaplin DJ.
    Acta Oncol; 1988 Sep; 27(6b):861-2. PubMed ID: 3233175
    [No Abstract] [Full Text] [Related]

  • 28. Misonidazole cytotoxicity in vivo: a comparison of large single doses with smaller doses and extended contact of the drug with tumor cells.
    Conroy PJ, Sutherland RM, Passalacqua W.
    Radiat Res; 1980 Jul; 83(1):169-89. PubMed ID: 7394163
    [No Abstract] [Full Text] [Related]

  • 29. Histopathological changes in transplanted mouse mammary carcinoma following hyperthermia with or without radiation.
    Jo S, Hiraoka M, Akuta K, Nishimura Y, Furuta M, Takahashi M, Abe M.
    Jpn J Cancer Res; 1986 Nov; 77(11):1095-101. PubMed ID: 3098719
    [Abstract] [Full Text] [Related]

  • 30. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.
    Mohamed F, Stuart OA, Glehen O, Urano M, Sugarbaker PH.
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851
    [Abstract] [Full Text] [Related]

  • 31. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.
    Hirst DG, Brown JM, Hazlehurst JL.
    Cancer Res; 1983 May; 43(5):1961-5. PubMed ID: 6682009
    [Abstract] [Full Text] [Related]

  • 32. Time-dose relationships for simultaneous misonidazole and 1,3-bis(2-chloroethyl)-1-nitrosourea exposures in vitro.
    Mulcahy RT, Dembs N.
    Cancer Res; 1983 Aug; 43(8):3539-43. PubMed ID: 6861127
    [Abstract] [Full Text] [Related]

  • 33. Testing of new hypoxic cell sensitizers in vivo.
    Stone HB, Sinesi MS.
    Radiat Res; 1982 Jul; 91(1):186-98. PubMed ID: 6212963
    [No Abstract] [Full Text] [Related]

  • 34. In vivo potentiation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea by the radiation sensitizer benznidazole.
    Siemann DW, Morrissey S, Wolf K.
    Cancer Res; 1983 Mar; 43(3):1010-3. PubMed ID: 6825075
    [Abstract] [Full Text] [Related]

  • 35. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G, Canal P, Mockey E, Vandevoorde E, Laurent F, Soula G.
    J Pharmacol; 1983 Mar; 14(1):67-77. PubMed ID: 6834852
    [Abstract] [Full Text] [Related]

  • 36. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors.
    Horowitz M, Blasberg R, Molnar P, Strong J, Kornblith P, Pleasants R, Fenstermacher J.
    Cancer Res; 1983 Aug; 43(8):3800-7. PubMed ID: 6861144
    [Abstract] [Full Text] [Related]

  • 37. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo.
    Overgaard J, Overgaard M, Nielsen OS, Pedersen AK, Timothy AR.
    Br J Cancer; 1982 Dec; 46(6):904-11. PubMed ID: 7150484
    [Abstract] [Full Text] [Related]

  • 38. Relationship between misonidazole toxicity and core temperature in C3H mice.
    Gomer CJ, Johnson RJ.
    Radiat Res; 1979 May; 78(2):329-33. PubMed ID: 451161
    [No Abstract] [Full Text] [Related]

  • 39. Enhancement of melphalan-induced tumour cell killing by misonidazole: an interaction of competing mechanisms.
    Horsman MR, Evans JW, Brown JM.
    Br J Cancer; 1984 Sep; 50(3):305-16. PubMed ID: 6466544
    [Abstract] [Full Text] [Related]

  • 40. [Biological and physical approach to the improvement of radiotherapy].
    Abe M, Ono K, Hiraoka M, Takahashi M, Nishidai T, Dodo Y, Jo S.
    Gan No Rinsho; 1983 Oct; 29(13):1570-3. PubMed ID: 6668666
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.